Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Evotec AG (OTC: EVOTF).

Full DD Report for EVOTF

You must become a subscriber to view this report.


Recent News from (OTC: EVOTF)

CENTOGENE and Evotec sign global strategic partnership on drug discovery projects in rare genetic diseases
CENTOGENE and Evotec AG ( OTCPK:EVOTF ) has entered into a global strategic collaboration agreement for joint drug discovery projects, developing compounds to treat rare genetic diseases. More news on: Evotec AG, Evotec AG ADR, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 27 2018 06:50
Evotec AG 2018 Q2 - Results - Earnings Call Slides
The following slide deck was published by Evotec AG in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: August, 12 2018 01:44
Evotec AG (EVOTF) CEO Werner Lanthaler on Q2 2018 Results - Earnings Call Transcript
Evotec AG (EVOTF) Q2 2018 Earnings Conference Call August 9, 2018 8:00 AM ET Executives Werner Lanthaler - Chief Executive Officer Mario Polywka - Chief Operating Officer Cord Dohrmann - Chief Scientific Officer Enno Spillner - Chief Financial Officer Analysts Falko Fried...
Source: SeekingAlpha
Date: August, 12 2018 01:40
Evotec forms LAB591 with Arix Bioscience and Fred Hutchinson Cancer Research Center
Evotec AG ( OTCPK:EVOTF ) forms LAB591 academic BRIDGE with Arix Bioscience and the Fred Hutchinson Cancer Research Center. More news on: Evotec AG, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 31 2018 08:22
Evotec's (EVOTF) CEO Werner Lanthaler on Q1 2018 Results - Earnings Call Transcript
Evotec AG (EVOTF) Q1 2018 Earnings Conference Call May 9, 2018 08:00 AM ET Executives Werner Lanthaler - CEO Mario Polywka - COO Cord Dohrmann - Chief Scientific Officer Enno Spillner - CFO Analysts Falko Friedrichs - Deutsche Bank Joseph Hedden - RX Securities Igor K...
Source: SeekingAlpha
Date: May, 09 2018 16:13
Evotec AG 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Evotec AG in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: May, 09 2018 08:26
Petra Pharma teams up with Evotec to develop lead candidate Petra-01
Privately held Petra Pharma enters into a collaboration with Evotec AG ( OTCPK:EVOTF ) under which it will access the latter's INDIGO platform to accelerate development through the IND stage of lead candidate Petra-01 for a range of cancers. More news on: Evotec AG, Healthcare stocks...
Source: SeekingAlpha
Date: April, 11 2018 07:16
Evotec AG 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by Evotec AG in conjunction with their 2017 Q4 earnings Read more ...
Source: SeekingAlpha
Date: March, 28 2018 14:40
Evotec's (EVOTF) CEO Werner Lanthaler on Q4 2017 Results - Earnings Call Transcript
Evotec AG (EVOTF) Q4 2017 Earnings Conference Call March 28, 2018, 08:00 ET Executives Werner Lanthaler - CEO Mario Polywka - COO Cord Dohrmann - Chief Scientific Officer Enno Spillner - CFO Analysts Falko Friedrichs - Deutsche Bank AG Francesco Gregori - Trinity Delta...
Source: SeekingAlpha
Date: March, 28 2018 14:35
Evotec AG reports FY results
Evotec AG ( OTCPK:EVOTF ): FY EPS of €0.16 More news on: Evotec AG, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: March, 28 2018 02:11

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-14N/A23.30N/AN/A0
2018-12-13N/A23.30N/AN/A0
2018-12-12N/A23.30N/AN/A0
2018-12-11N/A23.30N/AN/A0
2018-12-10N/A23.30N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-11-291,8222,32178.5006Short
2018-11-01100100100.0000Short
2018-09-111717100.0000Short
2018-07-24102104.7619Cover
2018-07-2010020050.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EVOTF.


About Evotec AG (OTC: EVOTF)

Logo for Evotec AG (OTC: EVOTF)

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand alone and integrated drug discovery solutions, covering all activities from target to clinic. The Company has established a unique position by assembling top class scientific experts and integrating state of the art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. lt br / gt lt br / gt Evotec has long term discovery alliances with partners including BoehringerIngelheim, CHDI, Genentech, Medimmune/AstraZeneca, Novartis and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and preclinical development. These include partnerships with Boehringer Ingelheim, MedImmune and with Andromeda Teva in the field of diabetes and with Roche in the field of Alzheimer s disease. Evotec is built on integrated drug discovery know how of more than years and is a leading player in the drug discovery field. The Company s headquarters are located in Hamburg, Germany. Additional major operations are based in Abingdon, UK, G ttingen, Munich, Germany, Thane, India and San Francisco, USA. Evotec has more than employees worldwide.

 

Contact Information

 

 

Current Management

  • Werner Lanthaler / CEO
  • Mario Polywka / COO
  • Colin Bond / CFO
  • Doris Kynast / IR, Corp. Commun.

Current Share Structure

  • Market Cap: $2,352,360,285 - 03/14/2018
  • Issue and Outstanding: 115,595,100 - 09/30/2011

 



Daily Technical Chart for (OTC: EVOTF)

Daily Technical Chart for (OTC: EVOTF)


Stay tuned for daily updates and more on (OTC: EVOTF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: EVOTF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EVOTF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of EVOTF and does not buy, sell, or trade any shares of EVOTF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/